Remdesivir reduced risk of Covid-19 deaths, but more studies needed: Gilead


Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill Covid-19 patients. The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials.

Remdesivir has been at the forefront of the battle against Covid-19 after the intravenously administered medicine helped shorten hospital recovery times in a clinical trial. Several.

This article is no longer available in our repository.

There could be multiple reasons for this.